ReviewCurrent hematologic malignancy reports2016
Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.
Review in Current hematologic malignancy reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 27 citations in OpenAlex.
- Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.American journal of hematology · 2020Trial
- Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML.BioMed research international · 2016Trial
- In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I.Molecules (Basel, Switzerland) · 2024Article
- Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.Cells · 2023Review
- Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019.JCO global oncology · 2021Article
- Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children.Paediatric drugs · 2021Review
- Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of tyrosine kinase inhibitors (TKIs) has fundamentally changed the management of chronic myeloid leukemia (CML). Disease progression to advanced phase (accelerated or blast phase) has been reduced to 1 to 1.5 % per year from more than 20 % per year in the pre-TKI era. However, once the disease has progressed to accelerated or blast phase, there is no consensus regarding optimal therapy. The prognosis of these patients is dismal with median survival ranging from 7 to 11 months. TKIs along with allogeneic hematopoietic cell transplantation are conventional strategies in managing these patients but there are very few long-term survivors. Advanced phase CML represents the new frontier for CML treatment where research is critically needed to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.